Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study.

PloS One
Xiang Yang ZhangThomas R Kosten

Abstract

Schizophrenic patients have higher smoking rates than the general population. Studies show that smoking may be a form of self-medication in an attempt to alleviate cognitive deficits in schizophrenic patients of European background. This study examined the relationships between smoking and cognitive deficits in Chinese schizophrenic patients, which have previously received little systemic study. We recruited 580 male chronic patients meeting DSM-IV criteria for schizophrenia and 175 male control subjects who were matched on age and education. The subjects completed a detailed cigarette smoking questionnaire, the Fagerstrom Test for Nicotine Dependence (FTND), and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Patients also were rated on the Positive and Negative Symptom Scale (PANSS), the Simpson and Angus Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal Involuntary Movement Scale (AIMS). All five RBANS subscales except for the Visuospatial/Constructional index showed significantly lower cognitive performance for schizophrenics than normal controls. The schizophrenic smokers scored lower than the schizophrenic non-smokers on the RBANS total score and the Visuospatial/Constructional a...Continue Reading

References

Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
May 1, 1995·Free Radical Biology & Medicine·G J WetscherR A Hinder
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·R FreedmanW Byerley
Jun 5, 1998·Schizophrenia Bulletin·L E AdlerR Freedman
Nov 13, 1998·The American Journal of Psychiatry·G W DalackJ H Meador-Woodruff
Dec 9, 1998·Journal of Clinical and Experimental Neuropsychology·C RandolphT N Chase
Oct 6, 1999·Archives of Environmental Contamination and Toxicology·D YildizD W Armstrong
Mar 7, 2001·Biological Psychiatry·P A NewhouseJ Corwin
Mar 20, 2001·Critical Reviews in Neurobiology·B Elvevåg, T E Goldberg
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tony P GeorgeBruce E Wexler
Sep 13, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert C SmithAngelica Kloos
Oct 5, 2002·The Journal of Clinical Psychiatry·Jose de LeonFrancisco J Diaz
Nov 5, 2002·Schizophrenia Research·Catherine HughesTonmoy Sharma
Dec 6, 2002·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Robert C. SmithAntonis Kotsaftis
Feb 20, 2003·Schizophrenia Research·Adrián LLerenaJose de Leon
Apr 10, 2003·The Psychiatric Clinics of North America·Tonmoy Sharma, Lena Antonova
Apr 11, 2003·Current Psychiatry Reports·Robert FreedmanSherry Leonard
Apr 12, 2003·Neurochemistry International·Zhi-Zhong GuanAgneta Nordberg
Mar 24, 2004·Neurology·A OttUNKNOWN EURODEM Incidence Research Group
Jan 1, 2005·Environmental Health Perspectives·Kimberly YoltonRichard Hornung
Jan 12, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·Jan-Erik Strand, Henrik Nybäck
Mar 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·M Carmen AguilarJose de Leon
Jul 16, 2005·The American Journal on Addictions·David KalmanTony P George
Sep 15, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert C SmithAlea Khan
May 9, 2006·Schizophrenia Research·Kristi A SaccoTony P George
Aug 29, 2006·Psychopharmacology·Francesco MussoGeorg Winterer
Oct 20, 2006·Schizophrenia Research·Carmel M LoughlandAnthony W Harris
Mar 14, 2007·International Review of Neurobiology·Laura F Martin, Robert Freedman
May 8, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Maria C Jockers-ScherüblKlaus-Peter Kühl
Jun 8, 2007·Cellular and Molecular Neurobiology·Enrique L M Ochoa, Jose Lasalde-Dominicci
Jul 7, 2007·Inhalation Toxicology·Birgul IsikRecep Isik
Aug 11, 2007·Neuropsychology Review·Gary E Swan, Christina N Lessov-Schlaggar
Dec 29, 2007·The American Journal of Drug and Alcohol Abuse·Edward F Pace-SchottRobert Stickgold
May 13, 2008·Schizophrenia Research·Tarek K Rajji, Benoit H Mulsant
Oct 23, 2008·Pharmacopsychiatry·A Mobascher, G Winterer
Nov 1, 2007·Journal of Dual Diagnosis·Sherry LeonardRobert Freedman

❮ Previous
Next ❯

Citations

Aug 11, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Rajeev KrishnadasRobin G McCreadie
Nov 28, 2012·European Psychiatry : the Journal of the Association of European Psychiatrists·H HoriH Kunugi
Nov 29, 2015·Psychiatry Research·Christian NúñezGildas Brébion
May 16, 2014·Schizophrenia Research·Faith DickersonRobert Yolken
Jul 24, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mei HanXiang Yang Zhang
Dec 24, 2018·Frontiers in Psychiatry·Aliya M LucatchTony P George
Nov 3, 2016·Journal of Clinical Psychopharmacology·Alexandre González-RodríguezMiquel Bernardo
Jan 15, 2021·Psychological Medicine·Elysha RinginTamsyn E Van Rheenen
Apr 22, 2021·International Journal of Psychiatry in Clinical Practice·Rongrong ZhuXiang Yang Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.